Original Articles: 2011 Vol: 3 Issue: 3
Formulation and in vitro evaluation of modified release Gliclazide tablet
In the present work, modified release gliclazide once a daily tablet were designed for non-insulin dependent diabetes for better patient compliance by direct compression method, HPMC was used as polymer, Dibasic calcium phosphate and Maltodextrin as binder for direct compression. Estimation of MR Gliclazide in the prepared tablet formulations was carried out at 226 nm in phosphate buffer pH 7.4. The prepared formulations were further evaluated for hardness, friability, drug content uniformity, in vitro dissolution time. for in vitro drug release pattern in pH 7.4phosphate buffer and short-term stability (at 40ºC/ 75% RH for 3 months) and drugexcipient interaction (IR spectroscopy) were studied. Short-term stability studies on the promising formulations indicated that there are no significant changes in drug content and invitro dissolution time.